Introduction
Glucocorticoids (naturally occurring or synthetic) are nor mally used to replace steroid hormones in patients with hor monal insufficiencies, as antiinflammatory drugs, and for di minishing the immunological response to a great variety of antigens, including transplanted organs. These drugs are nor mally synthesized either as glucocorticoid alcohols (GCAs) or derivatives of them (esters and acetals) (GCDs). The most common way to obtain a GCD is either by esterification with organic acids (e.g., valeric, acetic, or succinic) or inorganic acids (e.g., phosphoric) or by forming acetals from acetone (acetonides).
Several methods have been developed for the determina tion of a single GCA (1) (2) (3) (4) and for GCDs in pharmaceutical preparations and biological fluids (5, 6) . However, little atten tion has been paid to the simultaneous determination of both GCDs and GCAs, even though it was required for different pur-* Author to whom correspondence should be addressed.
poses such as pharmacokinetics studies in biological fluids and to investigate the stability of GCDs in vitro and in am poules following long-term storage (7) .
In this study, various high-performance liquid chromato graphic (HPLC) methods are reported for the baseline separa tion of some GCDs and their GCAs as possible hydrolysis prod ucts (7) . These separations were used for a further study on the stability of the GCD in an aqueous medium by controlling the most important variables of hydrolysis (time, pH, and tem perature). This study was extented to several pharmaceutical preparations containing these compounds.
Experimental

Chemicals
Fluorocortisone (FL) (9α-fluoro-llβ,17α,21-trihydroxypregn-4-ene-3,20-dione), fluorocortisone acetate (FLA), (fluo rocortisone 21-acetate), triamcinolone (TRI) (9α-fluorolip,16α,17α,21-tetrahydroxypregna-l,4-diene-3,20-dione), triamcinolone acetonide (TRA) (9α-fluoro-11β,16α,17α,21-tetrahydroxypregna-l,4-diene-3,20-dione cyclic 16,17 acetal), dexamethasone (DX) (9α-fluoro-llβ,17α,21-trihydroxy-16α-methyl-l,4-pregnadien-3,20-dion), dexamethasone 21-phosphate (DXP), betamethasone (BM) (9α-fluor-llβ,l7α,21-trihydroxy-16β-methyl-l,4-pregnadien-3,20-dion), betamethasone 21-valerate (BMV), deoxycorticosterone (DOC) (4-pregnen-21-ol-3,20-dione), and methylprednisolone (MPL) (6α-methyl 11β,17α,21-trihydroxy-l,4-pregnadiene-3,20-dione) were purchased from Sigma Chemical (St. Louis, MO). De flazacort (DF) (11β,21-dihydroxy-2'-methyl-5βH-pregna-l.4-diene[17,16-d]oxazole-3,20-dion 21-acetate) and its metabolite, 21-hydroxy-DF (DFM), were gifts from Marion Merrell Dow España (Madrid, Spain). Methanolic solutions of these compounds were prepared. All compounds were detected by HPLC with ultraviolet (UV) detection. Phosphoric acid of analysis grade was from Merck (Darmstadt, Germany). HPLC-grade acetonitrile was from Promochem (Wesel, Germany). Water was purified with a Milli-Q system (Millipore, Molsheim, France). Millipore 0.45-μm nylon filters (Bedford, MA) were also used. All other chemicals were of analytical reagent grade.
Apparatus
The chromatographic system consisted of the following com ponents, all from LDC Analytical (Riviera Beach, FL): a Constametric 4100 solvent delivery system, a spectromonitor 5000 photodiode-array detector covering the range of 190-360 nm and interfaced to a computer for data acquisition, and a recorder model CI 4100 data module. A Rheodyne 20-μL loop injector (Cotati, CA) and a Jones Chromatography block (heated series 7960) for controlling column temperature in the range of 30-60°C (Seagate Technology, Scotts Valley, CA) were also used. A Selecta (Barcelona, Spain) temperature-controlled water bath and a Digitronic Selecta temperature-controlled heater were used to control the hydrolysis temperature below and above 30°C ± 1, respectively. A reversed-phase Hypersil 5-ODS (250 × 4.6-mm i.d., 5 μm film thickness) column and a Spherisorb 5-ODS (10 v 4.6-mm i.d., 5 μm film thickness) guard column from Phenomenex (Torrance, CA) were also used.
Mobile phase
The mobile phase was prepared by mixing 1.2mM phos phoric acid (pH 3) with HPLC-grade acetonitrile in a required volume ratio by programming the pump. The acetonitrile and phosphoric acid solution was previously filtered under a vacuum through 0.45-μm nylon filters and degassed using he lium sparge.
Chromatographic analysis
Once the column was conditioned with the mobile phase, chromatograms were obtained at a temperature of 25°C. Pure methanol containing a single corticosteroid or an appropriate mixture of them was injected (20 μL). The flow rate was 1.0 mL/min, and the UV-diode-array detection (UV-DAD) range used was 190-360 nm. Corticosteroids were identified by com parison between the UV spectra of the chromatographic peaks and UV spectra of previously registered standards. After iden tification, subsequent confirmation was performed by injection of each one. Analysis was carried out at 245 nm.
Hydrolysis of GCDs and HPLC analysis
Hydrolysis of GCDs was carried out in the temperature range of 20-50°C. Solutions containing GCDs (10 μg/mL) and the in ternal standard (IS) (5 μg/mL) were prepared in various aqueous media: phosphoric acid (pH 3), acetate buffer (pH 4.7), phosphate buffer (pH 7.2), and sodium hydroxide (pH 9.3 and 12). Samples were analyzed in the range of 1 min-3 h. For shorter reaction times, hydrolysis was stopped by adding con centrated phosphoric acid; for longer reaction times, the mo bile phase containing phosphoric acid (pH 3) was used. GCD hydrolysis and GCA formation were assessed by plotting the peak area ratio (PAR) of the GCD or GCA to the IS (DOC or MPL) versus time. 
Sample preparation
Pharmaceutical samples such as injectables, tablets, creams, ointments, and coliriums containing GCDs were employed and processed by triplicate. Injectables (Trigon Depot) con taining 40 mg/mL TRA were diluted adequately with 20mM phosphate buffer (pH 7.2) to obtain two separate 5-μg/mL solutions. Coliriums (Colircusi DX) containing 1 mg/mL of DXP were adequately diluted with 20 mM phosphate (pH 7.2) to obtain two separate 10 μg/mL solutions. Tablets (Dezacor, 30 mg) containing DF were adequately pulverized. The fine powder was weighed in the amount of 0.37 g and adequately di luted with phosphoric acid solution (pH 3.0) or phosphate buffer (pH 7.2) to obtain two separate 8-μg/mL solutions. Creams (0.6 g Celestoderm V) containing 0.5 mg/g BMV or ointments (0.3 g Fludronef) containing 1 mg/g FLA were treated with 3 mL of 20mM acetate buffer (pH 5.5) and ade quately diluted to obtain separate 8-μg/mL solutions. The above samples contained 5 μg/mL of an IS (see Table I ).
Results and Discussion
Separation of GCDs in the presence of GCAs
It is known from the literature that some GCDs are vulner able to chemical and enzymatic hydrolysis, giving GCA com pounds (7) (8) (9) . For this reason and in order to undertake a fur ther hydrolysis study of GCDs in an aqueous medium, several simultaneous baseline separations involving GCD and GCA compounds using an IS (MPL or DOC) have been carried out. On the basis of other chromatographic studies previously de veloped (10-11) involving similar corticoids and several mobile phases, acetonitrile was selected as an organic modifier and op timized at a column temperature of 25°C. Table I shows a Table I. summary Figure 1 . These separations have the advantage of monitoring both GCD and GCA compounds. The broadening of DF and DFM peaks was probably due to interactions between the column (silanol groups) and nitrogen-containing compounds.
Calibration graphs
Standards containing mixtures of GCDs, GCAs, and the IS (Table I) were prepared at five different concentrations in the range of 2-10.0 μg/mL using 5.0 μg/mL IS (MPL or DOC). These solutions were analyzed with the mobile phases sum marized in Table I using a flow rate of 1.0 mL/min, a Hypersil column, and UV-DAD at 245 nm. Plotting each corticosteroid peak area to the IS ratio (PAR) versus the concentration (x), the calibration equations were obtained (PAR =A + Bx [μg/mL]). In Table II , the parameters A (intercept), Β (slope), and r (re gression coefficient) are shown. In all cases, the intercepts were not significantly different from zero.
Precision and detection limits
The precision was examined by analyzing 10 different sam ples of corticosteroids containing 6 μg/mL each by means of the calibration graphs. The relative standard deviation (RSD) for the corticoids under study is shown in Table II . The detec tion limits obtained for a signal-to-noise ratio of 3 are also in Table II . 
Preliminary hydrolysis test: GCA identification
To obtain preliminary information about the hydrolysis of GCDs, some experiments were performed under various pH conditions (pH 3-12). In such conditions, standards were maintained for 24 h at a reaction temperature of 25°C. For product identification, retention times and UV absorption spectra obtained from chromatographic peaks on Figure 1 were then compared with those obtained after reaction. In this way, all the proposed GCAs were identified. Exception was made with regard to TRA because two compounds were ren dered: TRI and an unknown compound with a UV spectrum similar to those of other glucocorticoids (OGC) with a higher retention time than TRI (more hydrophobic). This behavior suggests a double reaction mechanism involving a dihydroxy-(TRI) and a hydroxy-compound (OGC) (Figure 1 ). For quan titative assessment of the hydrolysis products, samples were an alyzed using the separations previously obtained (Table I and Figure 1 ) and calibration graphs.
The experimental data obtained from this study are sum marized in Table III . As can be observed, the hydrolysis did not occur at pH 3 but was favored in the alkaline medium, except DXP, which was hydrolyzed at pH 4.7. From these experiments, it could be concluded that the hydrolysis might be stopped either with mobile phases containing phosphoric acid (pH 3) or by adding this acid to the reaction mixture (see Hydrolysis of GCDs and HPLC analysis section). 
Influence of hydrolysis variables
Based on the above test, the hydrolysis of standard solu tions containing GCDs was studied considering the main vari ables that can affect these reactions (time, pH, and tempera ture). These effects were only studied when the hydrolysis was positive (Table III) . Peak area ratios of the consumed GCD or the produced GCA to the IS (DOC or MPL) were obtained under different hydrolysis conditions. After this, the hydrolysis percentage (% H) was obtained from calibration graphs.
The effect of temperature on GCD hydrolysis was studied in the range of 20-50°C at pH 12 for all GCDs except DXP and at pH 4.7 for DXP only. As can be observed in Figure 2 , all GCD Table I. compounds were affected by temperature. Hydrolysis increased when the temperature was increased. At 50°C, quantitative re sults were achieved for BMV (5 min), FLA (5 min), and DF (15 min). However, it was incomplete for TRA and DXP (to obtain 30% hydrolysis for TRA and 7% for DXP, 160 min was re quired).
The effect of pH was also studied (25°C) in the range of 3.0-12. Hydrolysis was observed in the pH range of 4.7-12 for FLA, BMV, and DF. However, TRA and DXP only afforded hy drolysis at pH 12 and 4.7 (Table III) . Figure 3 shows the FLA be havior versus hydrolysis as an illustrative example. As can be observed ( Figure 3A) , hydrolysis (40°C) increased with pH (e.g., at 20 min, quantitative hydrolysis was obtained at pH 12, but not at a lower pH). Figure 3B shows the effect of temper ature at a fixed time (20 min). At any pH value, hydrolysis in creased as temperature increased. These results are in agree ment with those obtained for similar compounds (7) .
Stability studies of GCDs in pharmaceuticals
Based on the above separations and hydrolysis tests, in vitro stability studies on different pharmaceutical preparations (Table IV) containing GCD compounds were carried out. From these data, physiological conditions (37°C) were selected. Hydrolysis reactions were assessed (maximum 48 h) from chro matographic data obtained by comparing samples under hy drolysis and nonhydrolysis conditions. In this way, the presence of interferences was tested. Table IV also summarizes the re coveries found (under sample preparation conditions) and the hydrolysis percentage obtained from pharmaceuticals con taining GCDs. Table V shows the hydrolysis percentage versus time for FLA at pH 7.2. As can be observed, hydrolysis in creased as time increased. Figure 4 shows the chromatograms obtained from two sam ples containing DXP (colirium) previously stored at room tem perature. One sample was used approximately 2 years ago, and the other was a fresh colirium. With regard to the old prepa ration, compounds Y (maximum wavelength, 200 and 251 nm) and Z (maximum wavelength, 256 nm) ( Figure 4B ) were preservative compounds containing samples that were not present in the new one ( Figure 4A ). Moreover, compound X presented the characteristic absorption spectrum of cortico steroids (maximum wavelength, 245 nm). This compound did not correspond to DX (see Figure 1) . As expected, DXP hydrolysis did not take place at pH 7.2. However, a more hydrophilic compound than DX was obtained ( Figure 4B ). This unknown compound may have been due to an impurity derived from the DXP synthesis or derived from an unknown degra dation process.
Samples containing DF (tablets) were also investigated. As expected, chemical hydrolysis in the stomach or duodenum for tablets practically did not take place. However, DF is converted to DFM by blood seric sterases (11) . Other investigated samples (Table IV) gave no positive results.
Conclusion
Different efficient chromatographic methods for pairs of corticoids have been developed that allow the simultaneous monitoring of GCDs and their hydrolysis products in a sensi tive and selective way. These methods hold special interest in their application to the analysis of different pharmaceutical preparations with different purposes, such as long-and shortterm stability and quality control.
